Common Contracts
7 similar Subscription and Investment Representation Agreement contracts by Aditxt, Inc., Allena Pharmaceuticals, Inc., Amesite Inc., others
Bellerophon Therapeutics, Inc. Series A Non-Convertible Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • January 30th, 2024 • Bellerophon Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT, dated as of January 25, 2024, is by and between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Aditxt, Inc. Series C Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • July 14th, 2023 • Aditxt, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT, dated as of July 11, 2023, is by and between Aditxt, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Amesite Inc. Series A Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • January 13th, 2023 • Amesite Inc. • Services-prepackaged software • Delaware
THIS AGREEMENT (this “Agreement”), dated as of January 13, 2023, is by and between Amesite Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Hoth Therapeutics, Inc. Series B Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • November 3rd, 2022 • Hoth Therapeutics, Inc. • Pharmaceutical preparations • Nevada
THIS AGREEMENT (this “Agreement”), dated as of November 2, 2022, is by and between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Aditxt, Inc. Series B Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • July 20th, 2022 • Aditxt, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT, dated as of July 19, 2022, is by and between Aditxt, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Allena Pharmaceuticals, Inc. Series F Non-Convertible Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • July 12th, 2022 • Allena Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT, dated as of July 12, 2022, is by and between Allena Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
Brickell Biotech, Inc. Series A Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • May 25th, 2022 • Brickell Biotech, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT, dated as of May 25, 2022, is by and between Brickell Biotech, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
